Patent intelligence · US
US 10420812
Drug combinations and uses in treating a coughing condition
Drug combinations and uses in treating a coughing condition
Patent details — US 10420812
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 24, 2019
- Expiration
- Sep 19, 2039
- Applicant
- Infirst Healthcare Limited
- Claims
- 15
- CPC classes
- A61K, A61K31/375, A61K31/522, A61K36/534
Quick answer
US 10420812 (Drug combinations and uses in treating a coughing condition) is held by Infirst Healthcare Limited. Status: granted. Granted Sep 24, 2019. Expires Sep 19, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Infirst Healthcare Limited
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/375, A61K31/522, A61K36/534, A61K45/06, A61K9/0053
More from Infirst Healthcare Limited
Related pharmaceutical patents in our USPTO index.
-
US 12357666
Traditional Chinese herbal plant composition for improving symptoms of liver cancer patients and compatibility method thereof
granted -
US 12228572
Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells
granted -
US 12220446
Use of upstream open reading frame 45aa-uORF nucleotide sequence of PTEN gene and polypeptide coded by 45aa-uORF
granted -
US 12090156
Application of CB-839 in preparation of drug for inhibiting corneal neovascularization (CNV)
granted -
US 12076443
Preparation method of nanozyme composite-based hybrid hydrogel eye drop
granted -
US 12016950
Devices and methods for treating ear pain
granted -
US 11992555
Solid solution compositions and use in chronic inflammation
granted -
US 11980602
Cannabinoid prodrug compounds
granted
Frequently asked questions
What is US patent 10420812?
US 10420812 (Drug combinations and uses in treating a coughing condition) is held by Infirst Healthcare Limited. Status: granted. Granted Sep 24, 2019. Expires Sep 19, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10420812?
Infirst Healthcare Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 123 pharmaceutical patents for this assignee.
When does US 10420812 expire?
Our index shows an expiration date of Sep 19, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.